Medtronic Finalizes $585M CathWorks Deal to Add AI-Powered FFRangio System
Medtronic has completed its $585 million acquisition of CathWorks, integrating its AI-powered, wire-free FFRangio System into Medtronic’s cardiovascular portfolio. The ALL-RISE trial’s one-year data from 1,900 patients across 59 global sites showed non-inferior MACE rates versus wire-based physiology with reduced procedure times and resource use.
1. Acquisition Completion and Terms
Medtronic has closed its $585 million purchase of CathWorks, securing full ownership of the FFRangio System following a 2022 co-promotion partnership. The deal includes potential undisclosed earn-out payments and positions Medtronic to integrate wire-free physiological assessment into its interventional cardiology lineup.
2. ALL-RISE Trial One-Year Results
The ALL-RISE randomized trial enrolled 1,900 patients at 59 sites across North America, Asia, Europe and the Middle East. After one year, the AI-driven FFRangio System demonstrated non-inferior major adverse cardiac event rates compared with wire-based fractional flow reserve, while reducing procedural time and resource utilization.
3. Financial and Earnings Impact
This acquisition is expected to be immaterial to Medtronic’s fiscal 2027 GAAP and adjusted earnings per share, shifting to neutral or modestly accretive performance thereafter. Management emphasizes that strategic tuck-in deals like this support long-term value creation without dilutive effects on near-term profits.
4. Technology Integration and Market Expansion
The FFRangio System leverages advanced computational science and artificial intelligence to deliver comprehensive coronary physiological assessment from routine angiograms without pressure wires or pharmacologic stress. Medtronic plans to scale deployment across its global sales channels in the U.S., Europe, Japan and other key markets.